Last edition
News about "clinical trial "
Meiji Seika Pharma Invests in Centivax for Universal Vaccine Platform
Meiji Seika Pharma invests in Centivax to advance a next-generation universal vaccine platform, with lead candidate Centi-Flu 01 currently in a Phase 1 influenza study.
Clinical Trial | 31/03/2026 | By News Bureau
Endogenex Raises USD 50 Million to Advance Novel Diabetes Treatment
Series C extension led by Arboretum Ventures to fund pivotal clinical study and support regulatory pathway for ReCET System.
Clinical Trial | 26/03/2026 | By News Bureau
Harbour BioMed Publishes Positive Phase I Data for HBM9378 in Immunology
Harbour BioMed reports favourable safety and pharmacokinetic profile for HBM9378 in Phase I trial, supporting further development for severe immunological disorders.
Clinical Trial | 23/03/2026 | By News Bureau
Biotheryx Doses First Patient in Dose Expansion Trial of BTX-9341 for Advanced Breast Cancer
Biotheryx advances BTX-9341 into a dose expansion trial with fulvestrant for HR+/HER2- breast cancer, aiming to overcome resistance in patients previously treated with CDK4/6 inhibitors.
Clinical Trial | 19/03/2026 | By News Bureau
BioVersys AG receives US Food and Drug Administration nod to include US patients in Phase III BV100 trial targeting drug-resistant pneumonia, marking progress in combating deadly hospital infections globally.
Clinical Trial | 18/03/2026 | By News Bureau
Aisa Pharma presented Phase II RECONNOITER trial results showing AISA-021 improved attack-free days and reduced duration of Raynaud’s attacks in systemic sclerosis patients at the World Systemic Sclerosis Congress.
Clinical Trial | 10/03/2026 | By News Bureau
HUTCHMED Starts Global Trial of HMPL-A580 for Solid Tumours
HUTCHMED has initiated a global clinical trial of HMPL-A580, a PI3K/PIKK-EGFR ATTC candidate, in patients with solid tumours. The study marks the second clinical programme from its next-generation ATTC platform, targeting both PAM pathway and EGFR signaling to enhance therapeutic synergy.
Clinical Trial | 06/03/2026 | By News Bureau
Centivax Begins Phase-I Trial of Universal Flu Vaccine
Unlike conventional seasonal influenza vaccines, which must be reformulated annually to attempt to match predicted circulating strains, Centi-Flu 01 is designed to focus both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate, and are shared across strains and distance subtypes.
Clinical Trial | 13/02/2026 | By News Bureau
PharmaResearch Wins FDA Clearance for Phase-I Trial of PRD-101
PRD-101 is a next-generation nano anti-cancer drug candidate formulated using nucleotide fragments produced through PharmaResearch's proprietary DOT (DNA Optimising Technology).
Clinical Trial | 07/02/2026 | By News Bureau | 173
SK Bioscience Begins Study of Sarbecovirus Vaccine
SK bioscience has initiated a global phase I/II clinical trial of GBP511, a universal vaccine candidate targeting the Sarbecovirus family, leveraging its SKYCovione recombinant protein platform and nanoparticle technology as part of the company’s mid- to long-term strategy to advance next-generation vaccines for future pandemic preparedness.
Clinical Trial | 30/01/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy